{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:58:29Z","timestamp":1775581109722,"version":"3.50.1"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Mirvetuximab Soravtansine (MIRV) is a promising antibody\u2012drug conjugate (ADC) that targets folate receptor alpha (FR\u03b1), which is overexpressed in several types of solid tumors. In November 2022, MIRV was approved in the USA for the treatment of adult patients with FR\u03b1-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who received 1\u20133 prior systemic treatment regimens. Therefore, high-quality evidence for its efficacy and safety in different cancers is urgently needed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A systematic search (e.g., PubMed, Embase, Web Of Science, Cochrane Library) was conducted to identify all relevant clinical trials of MIRV alone or in combination with chemo- and\/or target-therapies in solid tumors. The primary end-point was median progression-free survival (mPFS). The secondary endpoints were the Objective response rate (ORR) and adverse effects (AEs). A random-effects model was applied.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The study included nine research studies with a total of 682 patients. The pooled mPFS and pooled ORR were 6.70 months (95% CI 4.54\u20138.86, I2 = 96.21%) and 36% (95% CI: 28% to 44%, I2 = 76.79%), respectively. Significant differences were observed among intervention regimens and response to platinum. The pooled mPFS of MIRV monotherapy and MIRV+ Bevacizumab (BEV) combined therapy was 4.28 (95% CI 3.90\u20134.65, I2 = 0.00%) and 7.78 (95% CI 6.62\u20138.95, I2 = 0.00%), respectively. The pooled ORRs of MIRV monotherapy and MIRV+BEV combined therapy were 25% (95% CI 21%\u201329%, I2 = 25.20%) and 43% (95% CI 36%\u201350%, I2 = 0.01%), respectively. The pooled ORRs of the platinum-sensitive, platinum-resistant groups were 59% (95% CI 36%\u201381%, I2 = 61.88%), 33% (95% CI 25%\u201340%, I2 = 69.73%), respectively. In addition, we conducted supplementary subgroup analyses to explore the influence of FR\u03b1 receptor expression levels and the number of prior treatments on treatment outcomes. The most common adverse effects were blurred vision (45.20%), nausea (40.13%), diarrhea (39.52%), fatigue (33.84%) and keratopathy (31.20%).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>MIRV has significant therapeutic effects in solid tumors, especially when combined with BEV. In platinum-tolerant tumors, the efficacy of MIRV is also considerable. Overall, MIRV is relatively safe in solid tumors, and adverse reactions are relatively rare and mild.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0310736","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T18:35:54Z","timestamp":1735324554000},"page":"e0310736","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"19","author":[{"given":"Shamsnur","family":"Rehim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-1231","authenticated-orcid":true,"given":"Hongjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"pone.0310736.ref001","unstructured":"Ehrlich, P.B.e.-t.A.V.L., 1909; pp 165\u2212202."},{"key":"pone.0310736.ref002","doi-asserted-by":"crossref","first-page":"107917","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Y. Jin","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"2","key":"pone.0310736.ref003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.37349\/etat.2022.00077","article-title":"Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?","volume":"3","author":"M. Nerone","year":"2022","journal-title":"Explor Target Antitumor Ther"},{"issue":"4","key":"pone.0310736.ref004","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1185\/03007995.2013.775113","article-title":"Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.","volume":"29","author":"B. Boyraz","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"pone.0310736.ref005","doi-asserted-by":"crossref","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023.","volume":"15","author":"H. Kaplon","year":"2023","journal-title":"MAbs"},{"issue":"7","key":"pone.0310736.ref006","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a Folate Receptor-\u03b1 (FR\u03b1)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR\u03b1-Expressing Tumors","volume":"14","author":"O. Ab","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"pone.0310736.ref007","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010014","article-title":"Active Targeted Nanoformulations via Folate Receptors: State of the Art and Future Perspectives","volume":"14","author":"C. Mart\u00edn-Sabroso","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"pone.0310736.ref008","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","article-title":"Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments","volume":"26","author":"J.A. Ledermann","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"pone.0310736.ref009","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor \u03b1 in oncology","volume":"17","author":"M. Scaranti","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"pone.0310736.ref010","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1021\/jm060319f","article-title":"Semisynthetic maytansine analogues for the targeted treatment of cancer","volume":"49","author":"W.C. Widdison","year":"2006","journal-title":"J Med Chem"},{"issue":"1","key":"pone.0310736.ref011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1208\/s12248-019-0390-2","article-title":"A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects","volume":"22","author":"J.K. Burton","year":"2019","journal-title":". Aaps j"},{"key":"pone.0310736.ref012","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"BMJ (OPEN ACCESS)","year":"2021","journal-title":"BMJ"},{"key":"pone.0310736.ref013","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.","volume":"134","author":"M.J. Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"pone.0310736.ref014","article-title":"Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration","author":"J.P. Higgins","year":"2011","journal-title":"Retrieved from"},{"key":"pone.0310736.ref015","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"J.A.C. Sterne","year":"2016","journal-title":"BMJ"},{"key":"pone.0310736.ref016","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant."},{"key":"pone.0310736.ref017","volume-title":"Stata Statistical Software: Release 16","author":"StataCorp","year":"2019"},{"issue":"11","key":"pone.0310736.ref018","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"J.P. Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"2","key":"pone.0310736.ref019","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"W. Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"issue":"10","key":"pone.0310736.ref020","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"J.A. Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"pone.0310736.ref021","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"J.A. Sterne","year":"2011","journal-title":"Bmj"},{"issue":"6","key":"pone.0310736.ref022","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"K.N. Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"pone.0310736.ref023","first-page":"A13","article-title":"PHASE I STUDY OF MIRVETUXIMAB SORAVTANSINE (MIRV) AND RUCAPARIB FOR RECURRENT ENDOMETRIAL, OVARIANFALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER","volume":"31","author":"F. Backes","year":"2021","journal-title":". International Journal of Gynecological Cancer"},{"issue":"15","key":"pone.0310736.ref024","article-title":"A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected fr alpha-positive solid tumors: Results in the ovarian cancer (EC) cohort","volume":"39","author":"M.C. Cristea","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"pone.0310736.ref025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.","volume":"170","author":"L. Gilbert","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"2","key":"pone.0310736.ref026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"L.P. Martin","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"13","key":"pone.0310736.ref027","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"U.A. Matulonis","year":"2023","journal-title":". J Clin Oncol"},{"issue":"10","key":"pone.0310736.ref028","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.","volume":"35","author":"K.N. Moore","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0310736.ref029","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","article-title":"Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.","volume":"151","author":"K.N. Moore","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"2","key":"pone.0310736.ref030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"D.M. O\u2019Malley","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"3","key":"pone.0310736.ref031","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab Soravtansine: First Approval","volume":"83","author":"Y.A. Heo","year":"2023","journal-title":". Drugs"},{"issue":"1","key":"pone.0310736.ref032","first-page":"8","volume":"13","author":"FDA Gives Nod to Mirvetuximab Soravtansine","year":"2023","journal-title":"Cancer discovery"},{"issue":"9","key":"pone.0310736.ref033","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1021\/acs.molpharmaceut.9b00653","article-title":"Folate Receptor \u03b1-Targeted (89)Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer","volume":"16","author":"G.S. Heo","year":"2019","journal-title":"Mol Pharm"},{"issue":"6","key":"pone.0310736.ref034","article-title":"Development of Folate Receptor-Targeted PET Radiopharmaceuticals for Tumor Imaging-A Bench-to-Bedside Journey.","volume":"12","author":"S.D. Boss","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0310736.ref035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13550-018-0437-x","article-title":"Leveraging PET to image folate receptor \u03b1 therapy of an antibody-drug conjugate","volume":"8","author":"C. Brand","year":"2018","journal-title":"EJNMMI Res"},{"issue":"2","key":"pone.0310736.ref036","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer","volume":"14","author":"K.N. Moore","year":"2018","journal-title":"FUTURE ONCOLOGY"},{"key":"pone.0310736.ref037","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semcancer.2021.03.031","article-title":"Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer","volume":"77","author":"K. El Bairi","year":"2021","journal-title":"Seminars in cancer biology"},{"issue":"2","key":"pone.0310736.ref038","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).","volume":"163","author":"S. Gaillard","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"7889","key":"pone.0310736.ref039","first-page":"S45","article-title":"Overcoming resistance.","volume":"600","author":"A.B. Keener","year":"2021","journal-title":"Nature"},{"issue":"33","key":"pone.0310736.ref040","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).","volume":"39","author":"J. Hamanishi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0310736.ref041","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"E. Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol,"},{"issue":"7","key":"pone.0310736.ref042","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-021-00484-2","article-title":"The clinical development of antibody-drug conjugates\u2014lessons from leukaemia","volume":"18","author":"E. Jabbour","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"pone.0310736.ref043","doi-asserted-by":"crossref","first-page":"E263","DOI":"10.1016\/j.jfo.2021.10.012","article-title":"Corneal toxicity of mirvetuximab soravtansine: A case report","volume":"45","author":"L. Vuillemey","year":"2022","journal-title":"Journal Francais D Ophtalmologie"},{"issue":"6","key":"pone.0310736.ref044","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine","volume":"25","author":"U.A. Matulonis","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"pone.0310736.ref045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/ICO.0000000000001805","article-title":"Ocular Toxicity of Mirvetuximab","volume":"38","author":"E. Corbelli","year":"2019","journal-title":"CORNEA"},{"issue":"2","key":"pone.0310736.ref046","article-title":"STRATEGIES FOR COLLABORATIVE MANAGEMENT OF OCULAR ADVERSE EVENTS OF ELAHERET (MIRVETUXIMAB SORAVTANSINE) IN PATIENTS WITH FOLATE RECEPTOR ALPHA (FRa)-POSITIVE RECURRENT OVARIAN CANCER","volume":"50","author":"C. Arn","year":"2023","journal-title":"Oncology Nursing Forum"},{"key":"pone.0310736.ref047","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2023.101148","article-title":"Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology","volume":"46","author":"D.L. Richardson","year":"2023","journal-title":"Gynecologic Oncology Reports"},{"key":"pone.0310736.ref048","volume-title":"Common mistakes in meta-analysis and how to avoid them","author":"M. Borenstein","year":"2019"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T18:36:11Z","timestamp":1735324571000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310736"}},"subtitle":[],"editor":[{"given":"Cho-Hao Howard","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0310736","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]}}}